Skip to main content
SpringerLink
Log in
Book cover

Multidisciplinary Approaches to Common Surgical Problems pp 115–122Cite as

Complications of Inflammatory Bowel Disease: Initial Medical Management and Role of Endoscopy

  • Chapter
  • First Online:

  • 551 Accesses

Abstract

The two major forms of inflammatory bowel disease (IBD) are ulcerative colitis (UC) and Crohn’s disease (CD). UC only involves the colon, while CD can affect the entire gastrointestinal tract. UC is frequently complicated by severe colitis and at times fulminant colitis or toxic megacolon. Complications of CD include severe colitis, fibro-stenotic or inflammatory intestinal obstruction, and penetrating diseases of intra-abdominal abscess, fistula, and perianal disease. Medical therapy including corticosteroids and biologic therapies have limited effectiveness, and surgical intervention is frequently indicated. Successful management of these complex IBD complications requires a carefully planned multidisciplinary approach.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431–7.

    Article  PubMed  Google Scholar 

  2. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299–315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107(2):179–94. author reply 95

    Google Scholar 

  4. Grieco MB, Bordan DL, Geiss AC, Beil AR Jr. Toxic megacolon complicating Crohn’s colitis. Ann Surg. 1980;191(1):75–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60(7):937–43.

    Article  PubMed  Google Scholar 

  6. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(9):2272–80.

    Article  PubMed  Google Scholar 

  7. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146(3):835–48 e6.

    Article  PubMed  Google Scholar 

  8. Domenech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14(10):1373–9.

    Article  PubMed  Google Scholar 

  9. Criscuoli V, Casa A, Orlando A, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004;36(12):818–20.

    Article  CAS  PubMed  Google Scholar 

  10. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol. 2001;96(3):773–5.

    Article  CAS  PubMed  Google Scholar 

  11. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101(12):2857–65.

    Article  CAS  PubMed  Google Scholar 

  12. Maharshak N, Barzilay I, Zinger H, Hod K, Dotan I. Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: prevalence, risk factors, and prognosis. Medicine (Baltimore). 2018;97(5):e9772.

    Article  Google Scholar 

  13. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16(8):775–8.

    Article  PubMed  Google Scholar 

  14. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205–10.

    Article  CAS  PubMed  Google Scholar 

  15. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jones JH, Lennard-Jones JE. Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut. 1966;7(2):181–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103–10.

    Article  CAS  PubMed  Google Scholar 

  19. Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125(4):1025–31.

    Article  PubMed  Google Scholar 

  20. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841–5.

    Article  CAS  PubMed  Google Scholar 

  21. D’Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120(6):1323–9.

    Article  PubMed  Google Scholar 

  22. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94(6):1587–92.

    Article  CAS  PubMed  Google Scholar 

  23. Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10(2):73–8.

    Article  PubMed  Google Scholar 

  24. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(6):760–5.

    Article  CAS  PubMed  Google Scholar 

  25. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–59. quiz 60

    Google Scholar 

  26. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3):CD005112.

    Google Scholar 

  27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.

    Article  CAS  PubMed  Google Scholar 

  28. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–15.

    Article  CAS  PubMed  Google Scholar 

  30. Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1(1):15–24.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237–43.

    Article  CAS  PubMed  Google Scholar 

  32. Narula N, Fine M, Colombel JF, Marshall JK, Reinisch W. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis. 2015;21(7):1683–94.

    Article  PubMed  Google Scholar 

  33. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11.

    Article  CAS  PubMed  Google Scholar 

  34. Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):340–50 e6.

    Article  PubMed  Google Scholar 

  35. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012;107(11):1693–701.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34(2):125–45.

    Article  CAS  PubMed  Google Scholar 

  37. Hirai F, Andoh A, Ueno F, et al. Efficacy of endoscopic balloon dilation for small bowel strictures in patients with Crohn’s disease: a nationwide, multi-centre, open-label, prospective cohort study. J Crohns Colitis. 2018;12(4):394–401.

    Article  PubMed  Google Scholar 

  38. Bettenworth D, Gustavsson A, Atreja A, et al. A Pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohn’s disease. Inflamm Bowel Dis. 2017;23(1):133–42.

    Article  PubMed  Google Scholar 

  39. Ding NS, Yip WM, Choi CH, et al. Endoscopic dilatation of Crohn’s anastomotic strictures is effective in the long term, and escalation of medical therapy improves outcomes in the biologic era. J Crohns Colitis. 2016;10(10):1172–8.

    Article  PubMed  Google Scholar 

  40. Reutemann BA, Turkeltaub JA, Al-Hawary M, Waljee AK, Higgins PDR, Stidham RW. Endoscopic balloon dilation size and avoidance of surgery in stricturing Crohn’s disease. Inflamm Bowel Dis. 2017;23(10):1803–9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lan N, Shen B. Endoscopic stricturotomy with needle knife in the treatment of strictures from inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):502–13.

    Article  PubMed  Google Scholar 

  42. Nishida Y, Hosomi S, Yamagami H, et al. Analysis of the risk factors of surgery after endoscopic balloon dilation for small intestinal strictures in Crohn’s disease using double-balloon endoscopy. Intern Med. 2017;56(17):2245–52.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Campos C, Perrey A, Lambert C, et al. Medical therapies for stricturing Crohn’s disease: efficacy and cross-sectional imaging predictors of therapeutic failure. Dig Dis Sci. 2017;62(6):1628–36.

    Article  PubMed  Google Scholar 

  44. Chan WPW, Mourad F, Leong RW. Crohn’s disease associated strictures. J Gastroenterol Hepatol. 2018;33(5):998–1008.

    Article  PubMed  Google Scholar 

  45. Church PC, Turner D, Feldman BM, et al. Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn’s disease. Aliment Pharmacol Ther. 2015;41(2):153–66.

    Article  CAS  PubMed  Google Scholar 

  46. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875–80.

    Article  PubMed  Google Scholar 

  47. Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9(10):842–50.

    Article  PubMed  Google Scholar 

  48. Pescatori M, Interisano A, Basso L, et al. Management of perianal Crohn’s disease. Results of a multicenter study in Italy. Dis Colon Rectum. 1995;38(2):121–4.

    Article  CAS  PubMed  Google Scholar 

  49. McKee RF, Keenan RA. Perianal Crohn’s disease--is it all bad news? Dis Colon Rectum. 1996;39(2):136–42.

    Article  CAS  PubMed  Google Scholar 

  50. Platell C, Mackay J, Collopy B, Fink R, Ryan P, Woods R. Anal pathology in patients with Crohn’s disease. Aust N Z J Surg. 1996;66(1):5–9.

    Article  CAS  PubMed  Google Scholar 

  51. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn’s disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77(4 Pt 2):914–20.

    Article  CAS  PubMed  Google Scholar 

  52. Callen PW. Computed tomographic evaluation of abdominal and pelvic abscesses. Radiology. 1979;131(1):171–5.

    Article  CAS  PubMed  Google Scholar 

  53. Allen BC, Barnhart H, Bashir M, Nieman C, Breault S, Jaffe TA. Diagnostic accuracy of intra-abdominal fluid collection characterization in the era of multidetector computed tomography. Am Surg. 2012;78(2):185–9.

    PubMed  Google Scholar 

  54. Golfieri R, Cappelli A. Computed tomography-guided percutaneous abscess drainage in coloproctology: review of the literature. Tech Coloproctol. 2007;11(3):197–208.

    Article  CAS  PubMed  Google Scholar 

  55. Ananthakrishnan AN, McGinley EL. Treatment of intra-abdominal abscesses in Crohn’s disease: a nationwide analysis of patterns and outcomes of care. Dig Dis Sci. 2013;58(7):2013–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Gervais DA, Ho CH, O’Neill MJ, Arellano RS, Hahn PF, Mueller PR. Recurrent abdominal and pelvic abscesses: incidence, results of repeated percutaneous drainage, and underlying causes in 956 drainages. AJR Am J Roentgenol. 2004;182(2):463–6.

    Article  PubMed  Google Scholar 

  57. Siddiqui MR, Ashrafian H, Tozer P, et al. A diagnostic accuracy meta-analysis of endoanal ultrasound and MRI for perianal fistula assessment. Dis Colon Rectum. 2012;55(5):576–85.

    Article  PubMed  Google Scholar 

  58. Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn’s disease: future directions. Gut. 2018;67:1181.

    Article  CAS  PubMed  Google Scholar 

  59. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405.

    Article  CAS  PubMed  Google Scholar 

  60. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.

    Article  CAS  PubMed  Google Scholar 

  61. de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn’s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Color Dis. 2016;18(7):667–75.

    Article  Google Scholar 

  62. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20(11–12):1329–36.

    Article  CAS  PubMed  Google Scholar 

  63. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–9.

    Article  CAS  PubMed  Google Scholar 

  64. Davis KG, Johnson EK. Controversies in the care of the enterocutaneous fistula. Surg Clin North Am. 2013;93(1):231–50.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA

    Nicholas R. Crews

  2. Department of Gastroenterology, Indiana University Hospital, Indianapolis, IN, USA

    Matthew E. Bohm

Authors
  1. Nicholas R. Crews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew E. Bohm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew E. Bohm .

Editor information

Editors and Affiliations

  1. Department of Surgery, Tripler Army Medical Center, Honolulu, HI, USA

    Robert Lim

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Crews, N.R., Bohm, M.E. (2019). Complications of Inflammatory Bowel Disease: Initial Medical Management and Role of Endoscopy. In: Lim, R. (eds) Multidisciplinary Approaches to Common Surgical Problems. Springer, Cham. https://doi.org/10.1007/978-3-030-12823-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-12823-4_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-12822-7

  • Online ISBN: 978-3-030-12823-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation